Biodexa enrolls 100th patient in Serenta Phase 3 eRapa trial
BDRX•Biodexa enrolled its 100th patient in the Serenta Phase 3 eRapa trial for familial adenomatous polyposis, with a futility analysis expected early next year.
1. Trial enrollment
Biodexa reached 100 enrolled patients in the registrational Phase 3 trial of eRapa in familial adenomatous polyposis. The next readout is a pre-specified futility analysis expected early next year; management expects the study’s key interim decision point sooner than planned, based on the pace of disease progression events, and database lock is targeted around the end of next year.
